published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsAbd-Elsalam, 2020 1.21 [0.36; 4.12] Chen, 2020 0.56 [0.01; 30.20] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] HAHPS, 2020 7.00 [0.80; 60.90] HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89] HYCOVID, 2020 0.54 [0.21; 1.40] NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78] ORCHID, 2020 1.07 [0.54; 2.11] RECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] TEACH, 2020 1.07 [0.34; 3.37] 1.10[0.99; 1.22]Abd-Elsalam, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HAHPS, 2020, HC-nCoV (Shanghai), 2020, HYCOVID, 2020, NO COVID-19 (Lyngbakken), 2020, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020, TEACH, 2020110%8,150moderatelow deaths (time to event analysis only)detailed resultsRECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] 1.10[0.99; 1.23]RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 202020%6,569moderatenot evaluable clinical improvementdetailed resultsHuang, 2020 1.37 [0.73; 2.56] ORCHID, 2020 1.02 [0.73; 1.42] 1.09[0.81; 1.46]Huang, 2020, ORCHID, 202020%501moderatenot evaluable clinical improvement (14-day)detailed resultsChen, 2020 0.56 [0.13; 2.48] Huang, 2020 1.37 [0.73; 2.56] 1.14[0.56; 2.31]Chen, 2020, Huang, 2020215%55moderatenot evaluable clinical worseningdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] HAHPS, 2020 1.07 [0.63; 1.82] TEACH, 2020 1.80 [0.62; 5.21] 1.20[0.83; 1.72]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HAHPS, 2020, TEACH, 202030%460moderatenot evaluable death or ventilationdetailed resultsHYCOVID, 2020 1.12 [0.45; 2.79] RECOVERY, 2020 1.14 [1.03; 1.27] SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42] 1.14[1.03; 1.25]HYCOVID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 202030%6,023moderatenot evaluable PCR-negative conversiondetailed resultsHC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75] 0.46[0.04; 5.75]HC-nCoV (Shanghai), 202010%30moderatenot evaluable PCR-negative conversion (14-day)detailed resultsChen, 2020 1.42 [0.26; 7.76] Huang, 2020 1.09 [0.95; 1.26] 1.09[0.95; 1.26]Chen, 2020, Huang, 202020%55moderatenot evaluable PCR-negative conversion (7-day)detailed resultsHuang, 2020 1.20 [0.60; 2.40] 1.20[0.60; 2.40]Huang, 202010%22moderatenot evaluable radiologic improvement (14-day)detailed resultsHuang, 2020 1.33 [0.94; 1.88] 1.33[0.94; 1.88]Huang, 202010%22moderatenot evaluable ICU admissiondetailed resultsAbd-Elsalam, 2020 0.83 [0.35; 1.95] 0.83[0.35; 1.95]Abd-Elsalam, 202010%194moderatenot evaluable adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01] Huang, 2020 1.80 [0.14; 23.37] ORCHID, 2020 1.26 [0.56; 2.84] RECOVERY, 2020 1.36 [0.98; 1.90] TEACH, 2020 1.16 [0.55; 2.42] 1.29[0.99; 1.69]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020, Huang, 2020, ORCHID, 2020, RECOVERY, 2020, TEACH, 202060%5,707moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2020-11-28 00:26 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 508,656,657 - roots T: 290